Novo Nordisk Strikes $2B Deal for Obesity Drug
KEY TAKEAWAYS Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss ...
Managed Healthcare Executive2d
Novo Nordisk Extends Lowered Wegovy Price to Retail Pharmacies
Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...
Novo Nordisk to pay $2 billion for new weight loss drug
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Novo Nordisk Stock Rises Ahead of Data on Ozempic Ingredient's Ability to Lower Heart Risk
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Healthline7d
Compounding Pharmacies to Stop Making Ozempic, Zepound Knockoffs: What to Know
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
Yahoo Finance24d
Novo Nordisk Launches National "My Ozempic® Era" Campaign Celebrating Stories of Inspirational Ozempic® Patients
PLAINSBORO, N.J., March 3, 2025 /PRNewswire/ -- Novo Nordisk launched ... with type 2 diabetes with help from Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, along with diet and exercise.
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...